share_log

T2 Biosystems | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nathan D. Hukill(65.4%),CR Group L.P.(65.4%), etc.

T2 Biosystems | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nathan D. Hukill(65.4%),CR Group L.P.(65.4%), etc.

T2 Biosystems | SC 13D/A：超過5%持股股東披露文件(修正)-Nathan D. Hukill(65.4%),CR Group L.P.(65.4%)等
美股sec公告 ·  05/08 07:51
牛牛AI助理已提取核心訊息
In a recent filing with the United States Securities and Exchange Commission, Nathan D. Hukill, along with associated entities including CR Group L.P. and various CRG Partners funds, reported a significant change in their beneficial ownership of T2 Biosystems, Inc. The group now collectively owns 8,853,173 shares, representing approximately 65.4% of the company's issued and outstanding common stock. This change in ownership is a result of the cancellation of outstanding loans to T2 Biosystems by the reporting entities, as detailed in the amended Schedule 13D filed on May 7, 2024. The loans were originally part of a Term Loan Agreement dated December 30, 2016. The most recent acquisitions of shares by the group occurred on April 12 and May 3, 2024. The filing indicates that no other transactions in the common stock have been made by the reporting persons in the last 60 days.
In a recent filing with the United States Securities and Exchange Commission, Nathan D. Hukill, along with associated entities including CR Group L.P. and various CRG Partners funds, reported a significant change in their beneficial ownership of T2 Biosystems, Inc. The group now collectively owns 8,853,173 shares, representing approximately 65.4% of the company's issued and outstanding common stock. This change in ownership is a result of the cancellation of outstanding loans to T2 Biosystems by the reporting entities, as detailed in the amended Schedule 13D filed on May 7, 2024. The loans were originally part of a Term Loan Agreement dated December 30, 2016. The most recent acquisitions of shares by the group occurred on April 12 and May 3, 2024. The filing indicates that no other transactions in the common stock have been made by the reporting persons in the last 60 days.
在最近向美國證券交易委員會提交的一份文件中，內森·哈基爾以及包括CR集團有限責任公司和各種CRG Partners基金在內的關聯實體報告說，他們對T2 Biosystems, Inc.的實益所有權發生了重大變化。該集團現在共擁有8,853,173股股票，約佔該公司已發行和流通普通股的65.4％。所有權變更是申報實體取消了對T2 Biosystems的未償貸款的結果，詳情見2024年5月7日提交的經修訂的附表13D。這些貸款最初是2016年12月30日定期貸款協議的一部分。該集團最近一次的股票收購發生在2024年4月12日和5月3日。該文件顯示，在過去的60天中，申報人沒有進行任何其他普通股交易。
在最近向美國證券交易委員會提交的一份文件中，內森·哈基爾以及包括CR集團有限責任公司和各種CRG Partners基金在內的關聯實體報告說，他們對T2 Biosystems, Inc.的實益所有權發生了重大變化。該集團現在共擁有8,853,173股股票，約佔該公司已發行和流通普通股的65.4％。所有權變更是申報實體取消了對T2 Biosystems的未償貸款的結果，詳情見2024年5月7日提交的經修訂的附表13D。這些貸款最初是2016年12月30日定期貸款協議的一部分。該集團最近一次的股票收購發生在2024年4月12日和5月3日。該文件顯示，在過去的60天中，申報人沒有進行任何其他普通股交易。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。